These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Increased constitutive nitric oxide production by whole body periodic acceleration ameliorates alterations in cardiomyocytes associated with utrophin/dystrophin deficiency. Lopez JR; Kolster J; Zhang R; Adams J J Mol Cell Cardiol; 2017 Jul; 108():149-157. PubMed ID: 28623080 [TBL] [Abstract][Full Text] [Related]
13. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy. Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887 [TBL] [Abstract][Full Text] [Related]
14. A comparison of the bone and growth phenotype of Wood CL; Suchacki KJ; van 't Hof R; Cawthorn WP; Dillon S; Straub V; Wong SC; Ahmed SF; Farquharson C Dis Model Mech; 2020 Jan; 13(2):. PubMed ID: 31754018 [TBL] [Abstract][Full Text] [Related]
15. [Study on the gene knockout model mice of Duchenne muscular dystrophy]. Chen S; Zhang C; Liu X; Gao L; Zhang W; Huang W; Lu X; Wang Z Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 34(2):210-3. PubMed ID: 12947691 [TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy. Gutpell KM; Hrinivich WT; Hoffman LM PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927 [TBL] [Abstract][Full Text] [Related]
17. Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background. Rodrigues M; Echigoya Y; Maruyama R; Lim KR; Fukada SI; Yokota T Sci Rep; 2016 Dec; 6():38371. PubMed ID: 27924830 [TBL] [Abstract][Full Text] [Related]
18. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy. Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419 [TBL] [Abstract][Full Text] [Related]
19. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy. Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]